Cambridge, Massachusetts-based Akebia Therapeutics, a fully integrated biopharmaceutical company, has announced a major layoff in response to
the Food and Drug Administration rejected the company's most advanced experimental drug, an anemia pill known as vadadustat.
The Akebia Therapeutics reduction in workforce will impact approximately 150 employees.
According to a regulatory filing, "The Board of Directors of Akebia Therapeutics, approved a reduction of the Company’s workforce by approximately 42% across all areas of the Company following the receipt of a complete response letter from the U.S. Food and Drug Administration to the Company’s new drug application for vadadustat for the treatment of anemia due to chronic kidney disease in adult patients. This workforce reduction is expected to be substantially completed by the end of the second quarter of 2022. The reduction in force reflects the Company’s determination to refocus its strategic priorities around its commercial product.
Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?